The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations

Movement Disorders

Volumn 14, Issue 3, 1999, Pages 517-519

  Spieker, Sybille ^a   Löschmann, Peter Andreas ^a   Klockgether, Thomas ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; BUDIPINE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DYSKINESIA; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL;

ADULT; AGED; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; N-METHYLASPARTATE; PARKINSON DISEASE; PILOT PROJECTS; PIPERIDINES; SEVERITY OF ILLNESS INDEX;

EID: 17544399959     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(199905)14:3<517::AID-MDS1025>3.0.CO;2-U     Document Type: Article

References (18)

1. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 1995;701:13-18.
2. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996; 39:574-578.
3. Rabey JM, Nissipeanu P, Korczyn AD. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992;4:277-282.
4. Jellinger K, Bliesath H. Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo. J Neurol 1987; 234:280-282.
5. Klockgether T, Jacobsen P, Loschmann PA, Turski L. The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J Neural Transm Park Dis Dement Sect 1993;5:101-106.
6. Siegfried J, Fischer R. Budipine: a new chemical substance in the treatment of Parkinson's disease. In: Gerstenbrand F, Poewe W, Stern G, eds. Clinical Experiences With Budipine in Parkinson Therapy. Berlin Heidelberg: Springer, 1985:152-157.
7. Przuntek H, Stasch J-P. Biochemical and pharmacological aspects of the mechanism of action of budipine. In: Gerstenbrand F, Poewe W, Stern G, eds. Clinical Experiences With Budipine in Parkinson Therapy. Berlin Heidelberg: Springer, 1985:107-112.
8. Jackisch R, Huang HY, Reimann W, Limberger N. Effects of the antiparkinsonian drug budipine on neurotransmitter release in central nervous system tissue in vitro. J Pharmacol Exp Ther 1993; 264:889-898.
9. Menge HG, Brand U. Pharmacologic bases of antiparkinsonian therapy. In: Gerstenbrand F, Poewe W, Stern G, eds. Clinical Experiences With Budipine in Parkinson Therapy. Berlin Heidelberg: Springer, 1985:82-92.
10. Offermeier J, van Rooyen JM. The pharmacodynamics of budipine on central neurotransmitter systems. In: Gerstenbrand F, Poewe W, Stern G, eds. Clinical Experiences With Budipine in Parkinson Therapy. Berlin Heidelberg: Springer, 1985:93-106.
11. Klockgether T, Wüllner U, Steinbach JP, Petersen V, Turski L, Löschmann PA. Effects of antiparkinsonian drugs on central neurotransmitter systems. Eur J Pharmacol 1996;301:67-73.
12. Jackisch R, Kruchen A, Sauermann W, Hertting G, Feuerstein TJ. The antiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA receptor antagonists. Eur J Pharmacol 1994;264:207-211.
13. Kotter R. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog Neurobiol 1994;44:163-196.
14. Klockgether T, Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 1990;28:539-546.
15. Boldry RC, Papa SM, Kask AM, Chase TN. MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior. Brain Res 1995;692:259-264.
16. Bonuccelli U, Del Dotto P, Piccini P, Behge F, Corsini GU, Muratorio A. Dextromethorphan and parkinsonism [Letter]. Lancet 1992;340:53.
17. Montastruc JL, Rascol O, Senard JM, Rascol A. A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease [Letter]. J Neurol Neurosurg Psychiatry 1992;55:630-631.
18. Montastruc JL, Fabre N, Rascol O, Senard JM, Blin O. N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan [Letter]. Mov Disord 1994;9:242-243.